Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
Trial ID or NCT#
Status
Purpose
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy
Official Title
A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy
Eligibility Criteria
- - Renal biopsy findings consistent with IgA nephropathy - Treatment with an Angiotensin Converting Enzyme inhibitor (ACEi) and/or an Angiotensin II Receptor Blocker (ARB) for at least 90 days at the maximum approved (or tolerated) dose - Proteinuria > 1 gm/day at diagnosis of IgA nephropathy and Proteinuria > 0.50 gm/day at the second Screening Visit - Blood pressure controlled to ≤ 130/80 with angiotensin blockade with or without other anti-hypertensive agents
- - Recent use of cyclophosphamide, mycophenolate mofetil, azathioprine, or Rituximab. - Use of > 15 mg/day prednisone (or other corticosteroid equivalent).
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Richard Lafayette, MD
650-498-6063
View on ClinicalTrials.gov